Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 2, 2011, Pages

  Karmiris, Konstantinos ^a   Bielen, Didier ^a   Vanbeckevoort, Dirk ^a   Vermeire, Séverine ^a   Coremans, Georges ^a   Rutgeerts, Paul ^a   Van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Abdominal Imaging; Abdominal Surgery; Anti TNF Agents; Inflammatory Bowel Disease

Indexed keywords

INFLIXIMAB;

ARTICLE; CLINICAL ASSESSMENT; COLITIS; CONTROLLED STUDY; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIANAL FISTULIZING CROHN DISEASE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78751682552     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.10.022     Document Type: Article

References (24)

1. Sandborn W.J., Fazio V.W., Feagan B.G., et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003, 125:1508-1530.
2. Papadakis K.A., Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000, 119:1148-1157.
3. Tozer P.J., Whelan K., Phillips R.K., et al. Etiology of perianal Crohn's disease: role of genetic, microbiological and immunological factors. Inflamm Bowel Dis 2009, 15:1591-1598.
4. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulae in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
5. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
6. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single center cohort. Gut 2009, 58:501-508.
7. Haggett P.J., Moore N.R., Shearman J.D., et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995, 36:407-410.
8. Halligan S., Stoker J. Imaging of fistula in Ano. Radiology 2006, 239:18-33.
9. Van Assche G., Vanbeckevoort D., Bielen D., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003, 98:332-339.
10. Bell S.J., Halligan S., Windsor C.J., et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003, 17:387-393.
11. Ng S.C., Plamondon S., Gupta A., et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009, 104:2973-2986.
12. Van Bodegraven A.A., Sloots C.E., Felt-Bersma R.J., et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002, 45:39-45.
13. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5A-36A.
14. Parks A.G., Gordon P.H., Hardcastle J.D. A classification of fistula-in-ano. Br J Surg 1976, 63:1-12.
15. Schwartz D.A., Wiersema M.J., Dudiak K.M., et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001, 121:1064-1072.
16. Tougeron D., Savoye G., Savoye-Collet C., et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009, 54:1746-1752.
17. Stoker J., Rociu E., Schouten W.R., et al. Anovaginal and rectovaginal fistulas: endoluminal sonography versus endoluminal MR imaging. AJR Am J Roentgenol 2002, 178:737-741.
18. Lunnis P.J., Barker P.G., Sultan A.H., et al. Magnetic resonance imaging of fistula-in-ano. Dis Colon Rectum 1994, 37:708-718.
19. Parsi M.A., Lashner B.A., Achkar J.P., et al. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 2004, 99:445-449.
20. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002, 123:707-713.
21. Arnott I.D., McNeill G., Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003, 17:1451-1457.
22. Vermeire S., Louis E., Carbonez A., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002, 97:2357-2363.
23. Chapple K.S., Spencer J.A., Windsor A.C., et al. Prognostic value of magnetic resonance imaging in the management of fistula-in-ano. Dis Colon Rectum 2000, 43:511-516.
24. Spencer J.A., Chapple K., Wilson D., et al. Outcome after surgery for perianal fistula: predictive value of MR imaging. AJR Am J Roentgenol 1998, 171:403-406.